MRNA · 8-K · 20260930PR408289
Product / Drug Pipeline Progress
Moderna, Inc. · 2026-09-30 · Importance 34 · Surprise 42 · In source text
Moderna is preparing for the potential launch and scale-up of intismeran autogene after positive Phase 3 results, while advancing a broader oncology portfolio. The release states that Moderna’s infectious disease franchise now includes five approved vaccines. It cites the recent U.S. FDA approval of Moderna’s seasonal flu vaccine and European Commission marketing authorization of its seasonal flu plus COVID combination vaccine.
Key facts
- Moderna is preparing for the potential launch and scale-up of intismeran autogene following positive Phase 3 results. source
- Moderna’s infectious disease franchise includes five approved vaccines following the recent U.S. FDA approval of its seasonal flu vaccine and European Commission marketing authorization of its seasonal flu plus COVID combination vaccine. source
- Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. source
- Moderna continues to advance a broader oncology portfolio. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Moderna is preparing for the potential launch and scale-up of intismeran autogene following positive Phase 3 results. |